Important Dosage Notice
The appropriate dose and treatment schedule must be determined by a qualified healthcare professional.
Baricitinib dosing is not determined solely by tablet strength. The appropriate regimen depends on the disease being treated, age, kidney function, concomitant medicines, treatment response and the prescribing information applicable to the patient’s jurisdiction.
The supplied website brief identifies Barinib 2 mg and Barigen 4 mg. These product strengths should not be interpreted as instructions for self-treatment.
What Does 2 mg or 4 mg Mean?
The milligram amount identifies the quantity of baricitinib contained in the tablet.
- Barinib 2 mg: listed as containing 2 mg baricitinib.
- Barigen 4 mg: listed as containing 4 mg baricitinib.
A 4 mg tablet is not automatically appropriate for every patient requiring baricitinib. Likewise, a 2 mg tablet should not be used to independently construct a prescribed regimen.
Reference-Product Dosing
Current U.S. labeling provides indication-specific dosing. For example, the recommended adult rheumatoid arthritis dose is 2 mg once daily, while severe alopecia areata treatment can involve 2 mg once daily with an increase to 4 mg once daily when an adequate response has not occurred after the specified treatment period. U.S. dosing also contains specific recommendations for hospitalized adults with COVID-19 and for patients with renal impairment.
These details illustrate why the dose cannot be selected simply from the available commercial strengths.
Kidney Function
Kidney function is an important consideration for baricitinib because renal elimination contributes substantially to removal of the medicine from the body.
Current U.S. labeling recommends dose modification in patients with moderate or severe renal impairment and does not recommend baricitinib for certain patients with severe renal impairment depending on the indication.
Patients should therefore tell their healthcare professional about known kidney disease and provide current laboratory information when requested.
How Baricitinib Is Generally Taken
Baricitinib tablets are taken orally.
Depending on the indication and applicable product information, treatment is generally administered once daily.
Patients should:
- Take the medicine exactly as prescribed.
- Take it at approximately the same time each day when instructed.
- Avoid changing the prescribed dose independently.
- Avoid taking additional tablets to compensate for a missed dose unless specifically instructed.
- Follow the instructions accompanying the particular product.
Food Considerations
Baricitinib can generally be taken with or without food under current U.S. labeling.
Taking the medicine consistently in relation to meals can make the routine easier to remember, but patients should follow their specific prescribing instructions.
Missed Dose
If a dose is missed, patients should follow the missed-dose instructions provided with their prescription.
They should not automatically double the next dose.
If there is uncertainty about what to do after a missed dose, a pharmacist or healthcare professional can provide product-specific guidance.
Treatment Consistency
Baricitinib works through ongoing modification of immune signaling. Consistency with the prescribed treatment schedule is therefore important.
However, treatment consistency does not mean continuing the medicine regardless of symptoms. A healthcare professional may temporarily interrupt treatment if clinically significant infection, laboratory abnormality or another safety issue develops.
Monitoring
Depending on the indication and patient, monitoring may include:
- Complete blood counts
- Liver-related laboratory testing
- Kidney function
- Lipid parameters
- Infection assessment
- Tuberculosis evaluation
- Symptoms suggesting thrombosis
- Cardiovascular risk assessment
The monitoring schedule should be individualized.
Vaccination
Vaccination status should be reviewed before treatment when appropriate. Live vaccines require particular consideration in patients receiving immunomodulatory therapy.
Patients should discuss planned vaccinations with their healthcare professional rather than making assumptions about vaccine timing.
Dose Changes
A healthcare professional may interrupt or modify treatment because of:
- Serious infection
- Abnormal blood counts
- Kidney impairment
- Laboratory abnormalities
- Other clinically important adverse reactions
- Drug interactions
- Disease-specific treatment considerations
Dose modification should never be performed independently.
Storage
Storage requirements should be taken from the package and official product information for the specific baricitinib product.
Patients should keep medicines away from children and should not use tablets after the stated expiry date.